Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance.
The anti-ischemic effects of organic nitrates are rapidly attenuated due to the development of nitrate tolerance. The mechanisms underlying this phenomenon likely involve several independent factors. As a vasodilator, nitroglycerin activates compensatory neurohumoral mechanisms such as the renin-angiotensin system and increases catecholamine and vasopressin levels, all of which may attenuate its vasodilator potency. Tolerance may be also due to the inability of the vessel to dilate after prolonged treatment with the nitrate. More recent experimental studies have challenged traditional tolerance concepts by demonstrating that tolerance is not associated with sulfhydryl group depletion, reduced nitroglycerin biotransformation, or desensitization of the target enzyme guanylyl-cyclase. Experimental and clinical observations suggest that tolerance may be the consequence of intrinsic abnormalities of the vasculature, including enhanced endothelial production of oxygen-derived free radicals secondary to an activation of NAD(P)H-dependent oxidases and an activation of PKC. Superoxide degrades nitric oxide derived from nitroglycerin (NTG) while C activation causes enhanced sensitivity of the vasculature to circulating neurohormones such as catecholamines, angiotensin II, and serotonin, all of which may compromise the vasodilator potency of NTG. Interestingly, these vascular consequences of in vivo NTG treatment such as superoxide production and PKC activation can be mimicked in vitro by incubating cultured endothelial and smooth muscle cells with angiotensin II. Furthermore, nitrate tolerance and rebound following sudden cessation of prolonged NTG therapy can be prevented by concomitant treatment with high-dose angiotensin-converting enzyme inhibition, angiotensin type 1 receptor blockade, or antioxidants such as hydralazine. Thus one can conclude that neurohumoral counterregulatory mechanisms such as increased circulating levels of angiotensin II may be at least in part responsible for tolerance mechanisms at the cellular level.
Münzel
T
T
Division of Cardiology II Medizinische Klinik, Universitätskrankenhaus Eppendorf, Hamburg, Germany.
Harrison
D G
DG
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology / Q000378:metabolism; D004361:Drug Tolerance; D005609:Free Radicals; D006801:Humans; D009566:Nitrates / Q000494:pharmacology*; D011493:Protein Kinase C / Q000187:drug effects / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000502:physiology*
D005609:Free Radicals; D009566:Nitrates; D017382:Reactive Oxygen Species; D011493:Protein Kinase C